Cowen initiated coverage on Aura Biosciences
$AURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cowen initiated coverage of Aura Biosciences with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $22.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $21.00 | Buy | H.C. Wainwright |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 4/17/2023 | $38.00 | Buy | BTIG Research |
| 7/19/2022 | $26.00 | Mkt Outperform | JMP Securities |
| 11/24/2021 | $40.00 | Outperform | SVB Leerink |
| 11/23/2021 | $38.00 | Buy | BTIG Research |
| 11/23/2021 | Outperform | Cowen |
144 - Aura Biosciences, Inc. (0001501796) (Subject)
10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET. The live webcast of the presentation will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the p
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights. "We continued to focus on execution in our clinical programs in the se
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and
H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00
Scotiabank initiated coverage of Aura Biosciences with a rating of Sector Outperform
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)